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In elderly (75 years) individuals, age-associated physiologic changes and a higher prevalence of
comorbidities, polypharmacy, and increased susceptibility to medication-induced side effects complicate
pain management. Hysingla ER (HYD) is a once-daily, single-entity, extended-release hydrocodone
formulation approved for the treatment of chronic pain that is insufﬁciently controlled by alternative
treatments. In this post-hoc analysis of a previously reported study, the effectiveness and safety of HYD
for the treatment of moderate-to-severe chronic pain among the elderly (75 years) for a 52-week
duration was investigated. HYD dose administered during the maintenance period-remained relatively
stable and provided clinically meaningful decreases in mean “pain over the last 24 h” and pain inter-
ference scores. Patients achieved pain control without additional non-study opioid use at the end of the
study. Adverse events were typical of opioids. In summary, HYD provided clinically meaningful reduction
of pain scores in elderly patients that were maintained over a 52-week period.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Improvements in medicine have prolonged the lives of Ameri-
cans over the past century, and Americans 65 years of age and older
now constitute 13.7% of the United States (US) population (43.1
million in 2012), with approximately 45% of them being 75 years or
older.1 Aging is often accompanied by a proliferation of health is-
sues; a signiﬁcant proportion of the growing elderly population has
multiple chronic conditions including arthritis, diabetes, respira-
tory disease, hypertension, and heart disease. Chronic pain is also a
prevalent condition among the elderly, reported to affect 81.1% of
those 78 years of age and 56.3% of those 85 years of age.2 Moderate
and severe symptoms of pain are noted by approximately 60% and
25% of adults over the age of 65, respectively.3 Treatment of pain in
the elderly (>65 years) is complicated by physiological changes
that accompany aging, including changes in the perception ofesser Boulevard, Stamford, CT
Inc. This is an open access article upain.3,4 Chronic pain management among the elderly is complex
and multifactorial, and frequently entails increased
polypharmacy.5,6
The World Health Organization’s 3-step pain ladder commonly
serves as a framework for the pharmacological management of pain
in adults.6 Treatment of low-intensity pain typically involves the
administration of non-opioid analgesics such as acetaminophen or
non-steroidal anti-inﬂammatory drugs (NSAIDs), with or without
adjuvants (Step 1). For moderate-intensity pain, a non-opioid anal-
gesic, together with a mild opioid such as tramadol and hydro-
codone, is generallyadministered (Step2). For patients experiencing
severe pain, treatment with a strong opioid such as morphine,
oxycodone, or fentanyl is considered appropriate (Step 3).
However, although the WHO analgesic ladder has been adapted
for pain management in the elderly,7 pain management in this
vulnerable population is different from the general population in
many ways. Due to a lack of clinical trial data in the elderly, pain
management guidelines need to be adapted to address the issues of
increased concurrent illnesses, polypharmacy, susceptibility to
adverse events (AEs), and physiological changes that impact efﬁ-
cacy of treatment.6e9 The elderly patient’s condition is oftennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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management in the elderly, therefore, requires a multidisciplinary
approach including pharmacotherapy and nonpharmacological
interventions such as physical therapy, and cognitive therapy.
Nonpharmacological interventions such as physical therapy, and
cognitive therapy should be considered for elderly patients with
chronic pain, although combined treatment with pharmacotherapy
is generally more effective.6
The complex and multimodal interactions of aging, concurrent
comorbidities, and polypharmacy present a substantial challenge
to the medical management of pain in the elderly and frail patient
subgroup whose pain control is consequently often found to be
suboptimal.6,7,10 Hysingla ER (Purdue Pharma L.P., Stamford, CT;
hereafter HYD) is a once-daily, single-entity, extended-release
hydrocodone bitartrate tablet with abuse-deterrent properties. In
November 2014, HYD was approved for use in the US for the
management of pain severe enough to require daily, around-the-
clock, long-term opioid treatment and for which alternative treat-
ment options are inadequate.11 In a previously reported phase 3
multicenter, double-blind, placebo-controlled trial, HYD was
demonstrated to be an effective analgesic for the treatment of
chronic lower back pain over a 12-week duration,12 consistent with
Food and Drug Administration (FDA) requirements for opioid an-
algesics used for chronic pain.13 Simultaneously with the random-
ized controlled trial, a separate open-label phase 3 multicenter
study established the safety and effectiveness of HYD over a 52-
week period in treating patients with persistent, moderate-to-
severe nonmalignant and non-neuropathic pain.14 While it is
recognized that non-drug therapies play an important part in the
management of chronic pain, this report presents a post-hoc
analysis of this open-label study of an opioid analgesic, per-
formed to examine the long-term effectiveness and tolerability of
HYD among a subpopulation of elderly study participants 75
years of age who were experiencing chronic pain.
Material and methods
Study design
This was a post-hoc analysis of data from an open-label, multi-
center study that assessed the long-term safety and effectiveness of
HYD 20e120 mg tablets, taken once-daily in opioid-naïve and
opioid-experienced patients with chronic, moderate-to-severe
nonmalignant and non-neuropathic pain (ClinicalTrials.gov,
NCT01400139).14 In the study, eligible patients received a starting
HYD dose of 20 mg, 40 mg, 60 mg, or 80 mg, depending upon their
incoming opioid dose. Hydrocodone-equivalent total opioid daily
dosewas calculated using conversion factors employed in the study
protocol.14 Ifmore than1 incomingopioid hadbeenused, the overall
total daily dose was the sum of all individual opioid daily
hydrocodone-equivalents. HYD dose adjustments (up to 120 mg)
were permitted during a 45-day titration period. Patients achieving
a stable dosewere enrolled into a 52-weekmaintenance period, and
continued treatment at the stable dose. The dose of HYD that was
administered for at least 7 days and provided acceptable pain relief
and tolerability was regarded as the stable dose. Dose alterations
were permitted as necessary throughout the maintenance period.
Patients
In this post-hoc analysis, the long-term safety and analgesic
effectiveness of HYD among a subpopulation of elderly (75 years
of age) patients were drawn from the patient population of a pri-
mary study, which enrolled eligible patients who were 18 years of
age or older. Patients were eligible to participate in the primarystudy if they were experiencing chronic, moderate-to-severe
nonmalignant and non-neuropathic pain over several hours a
day, for at least 3 months prior to the start of screening. Patients
could have been either opioid-naïve (ie, patients with an incoming
opioid dose equivalent to <5 mg/day of oxycodone) or opioid-
experienced. Patients taking 120 mg oxycodone equivalent
opioid analgesics within 14 days of the screening visit were
excluded. Patients with neuropathic pain, an underlying gastroin-
testinal condition, uncontrolled gout, pseudogout, psoriatic
arthritis, active Lyme disease, rheumatoid arthritis or other in-
ﬂammatory arthritis, uncontrolled psychiatric disorders, unstable
cardiac or respiratory disease, impaired liver or renal function, or a
history of substance abuse were not eligible for this study. Patients
were included in the primary study if they were capable of sub-
jective evaluation (ie, pain scores); were able to read and under-
stand questionnaires; were willing and able to use an electronic
diary; and were able to read, understand and sign the written
informed consent form. All patients participating in the study
provided written informed consent.
Assessments
At the start of the screening period, baseline information was
documented. The patient’s demographic information, medical
history and current medical conditions, pain history and etiology,
and pain rating (“average pain over the last 14 days” measured on
an 11-point numerical rating scale [NRS] where 0 ¼ no pain and
10 ¼ worst pain imaginable) were recorded. The use of NRS to
assess pain intensity in an elderly cohort has been validated.10,15 In
addition, the patient’s medications were recorded, as were non-
drug therapies used over the previous 30 days. Patients recorded
“average pain over the last 24 h” scores in an electronic diary, at
approximately 8 PM every day. Pain interference with activities of
daily living (general activity, walking, work, mood, enjoyment of
life, relations with others, and sleep) was also assessed using the
Brief Pain Inventory e short form (BPI-SF) survey on a 0 to 10 scale,
where a higher score indicates more interference. BPI-SF has been
validated and used in populations that include those 65 years of age
or older.15 A treatment satisfaction questionnaire was administered
to patients at week 4 of the maintenance period (or the end of
study/early discontinuation for patients who discontinued study
prior to week 4); week 4 was chosen as the administration time-
point so that patients could reasonably be expected to compare
their satisfaction of HYD to that of their baseline regimen. Safety
measures included AEs, clinical laboratory test results (complete
blood count with differential, urinalysis, blood chemistry panel),
vital sign measurements, and electrocardiogram ﬁndings.
Other medications
The use of supplemental opioid (excluding controlled-release or
long-acting medications) and non-opioid analgesics was permitted
throughout the study. Non-opioid analgesics were permitted if
maintained at a stable regimen throughout the duration of the
study. Medications that were started before the ﬁrst dose of HYD
was administered were considered prior medications, regardless of
whether their use was continued into the study period or not.
Medications taken after the ﬁrst dose of HYD was administered
were considered concomitant medications, irrespective of the
duration of their use.
Statistical analysis
Statistical Analysis System (SAS) version 9.3 was used to
conduct statistical analyses. Other validated statistical softwarewas
Table 1
Patient characteristics at screening, prior and concomitant pain medications, and starting HYD dose.
Patient no.
sex/age
(years)/BMI
(kg/m2)
Pain etiology Other relevant
medical condition
Relevant prior
medicationsa
Relevant
concomitant
medications
Pain scoreb,c Pain interference
score
Screening
opioid
dosed
(mg/day)
Starting
maintenance
HYD dose
(mg/day)
Screening Week
52
Screening Overall
maintenance
Patient 1
82/M/27.9
Osteoarthritis,
arthralgia, and
musculoskeletal
pain
Gastroesophageal reﬂux disease, edema
peripheral, arrhythmia, venous
insufﬁciency, and neuropathy
peripheral
Diclofenac and
glucosamine
Naproxen 3.8 3.5 2.9 0.4 e 20 mg
Patient 2
81/M/31.1
Arthralgia Atrial ﬁbrillation, coronary artery
disease, intermittent claudication, type
2 diabetes mellitus, diabetic
neuropathy, hyperlipidemia,
hypertension, bone erosion, osteolysis,
insomnia, venous insufﬁciency, age-
related macular degeneration, and
edema peripheral
Acetaminophen/
hydrocodone,
paracetamol,
zolpidem,
and dozol
Zolpidem, nebivolol, insulin glargine,
metformin, nifedipine, and atorvastatin
5.2 1.0 3.6 0.1 e 40 mg
Patient 3
81/F/23.1
Neck pain,
musculoskeletal
pain
Depression, glaucoma, osteoporosis,
and hypothyroidism
Oxymorphone
and venlafaxine
Venlafaxine, brimonidine, dorzolamide,
methazolamide, timolol, and travoprost
3.0 6.9 2.6 2.5 e 60 mg
Patient
4 84/F/26.4
Back pain,
intervertebral
disc
degeneration,
lumbar spinal
stenosis, spinal
compression
fracture, facet
joint syndrome,
and scoliosis
Anxiety, coronary artery disease,
cardiac failure congestive, renal artery
stenosis, dyslipidemia, facet joint
syndrome, myocardial ischemia, mitral
valve incompetence, pulmonary valve
incompetence, tricuspid valve
incompetence, osteopenia,
gastroesophageal reﬂux disease, and
hypertension
Acetaminophen/
hydrocodone
and lorazepam
Acetaminophen/hydrocodone,
lorazepam, atenolol, olmesartan,
dexlansoprazole, atorvastatin,
lisinopril, lorazepam, glyceryl trinitrate,
pantoprazole, and alprazolam
5.6 e 4.7 5.9 e 80 mg
Patient 5
78/M/26.4
Intervertebral
disc degeneration,
spinal pain,
osteoarthritis,
and arthralgia
Spinal nerve stimulator implantation,
hypertension, cerebrovascular
insufﬁciency, and blood cholesterol
increased
Paracetamol Paracetamol, rosuvastatin, lisinopril,
and clopidogrel
6.8 e 3.9 e e Titration
failure,
did not
qualify;
patient
found
unsuitable
upon
review of
medical
history
per PI
Patient 6
78/M/26.6
Back pain and
osteoarthritis
Gastroesophageal reﬂux disease,
hypercholesterolemia, hypertension,
and peripheral vascular disorder
Celecoxib Fentanyl, celecoxib, acetaminophen/
hydrocodone, carotid angiography with
stenting, heparin, midazolam,
nicardipine, lisinopril, omeprazole,
clopidogrel, pravastatin, and tamsulosin
8.3 e 2.9 0.0 e 40
Patient 7
75/M/26.9
Osteoarthritis
and arthralgia
Hyperlipidemia, aortic arteriosclerosis,
and chronic obstructive pulmonary
disease
Ibuprofen Ibuprofen 6.3 5.0 4.7 2.6 e 40
Patient 8
77/M/24.4
Osteoarthritis
and back pain
Pain in extremity, peroneal nerve palsy,
pulmonary embolism,
gastroesophageal reﬂux disease, and
foot deformity
Ibuprofen Fluoxetine, ibuprofen, morphine,
oxycocet, paracetamol, warfarin,
heparin, enoxaparin, and tamsulosin
7.3 4.0 5.7 3.2 e 40
(continued on next page)
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Table 1 (continued )
Patient no.
sex/age
(years)/BMI
(kg/m2)
Pain etiology Other relevant
medical condition
Relevant prior
medicationsa
Relevant
concomitant
medications
Pain scoreb,c Pain interference
score
Screening
opioid
dosed
(mg/day)
Starting
maintenance
HYD dose
(mg/day)
Screening Week
52
Screening Overall
maintenance
Patient 9
75/F/42.7
Arthralgia, joint
range of motion
decreased, back
pain, and
arthralgia
Atrial ﬁbrillation, depression, gout,
neuropathy peripheral, hyperlipidemia,
hypertension, hypothyroidism,
neuropathy peripheral, and restless legs
syndrome
Cyclobenzaprine,
gabapentin,
acetaminophen/
hydrocodone,
ropinirole, and
sertraline
Cyclobenzaprine, gabapentin,
acetaminophen/hydrocodone,
ropinirole, sertraline, allopurinol,
colchicine, furosemide, lisinopril,
metoprolol, pravastatin, ropinirole,
levothyroxine, and warfarin
8.6 4.3 6.1 4.6 e 40
Patient 10
77/M/24.3
Intervertebral
disc degeneration
Gastroesophageal reﬂux disease and
hypertension
Naproxen,
gabapentin, and
acetaminophen/
hydrocodone
Naproxen, gabapentin, and lisinopril 6.9 e 2.6 e e Titration
failure, AE
Patient 11
77/F/31.5
Spinal
osteoarthritis
Hyperlipidemia, hypothyroidism, and
insomnia
Tramadol,
ibuprofen,
and zolpidem
Tramadol, ibuprofen, zolpidem, and
levothyroxine
6.6 5.6 6.1 3.4 e 20
Patient 12
82/M/26.6
Spinal
osteoarthritis
and back pain
Atrial ﬁbrillation Acetaminophen/
hydrocodone,
methocarbamol,
and paracetamol
Diclofenac, methocarbamol, and
warfarin
2.4 e 2.0 2.5 e 40
Patient 13
81/M/30.6
Back pain,
arthralgia, and
intervertebral
disc protrusion
Headache, neck pain, hyperlipidemia,
hypertension, and hypothyroidism
Butalbital with
aspirin/caffeine
and
acetaminophen/
hydrocodone
Butalbital with aspirin/caffeine,
amlodipine, atenolol, levothyroxine,
and simvastatin
6.0 e 3.3 0.7 e 20
Patient 14
77/F/33.0
Osteoarthritis Depression, hypertension,
hypercholesterolemia, hypothyroidism,
and osteopenia
Ibuprofen,
chondroitin,
and glucosamine
Ibuprofen, chondroitin, and
glucosamine, enap-HL, simvastatin, and
levothyroxine
8.8 e 9.3 e e Titration
failure, AE
Patient 15
76/M/23.0
Back pain,
osteoarthritis,
and spinal
osteoarthritis
Insomnia neuropathy peripheral,
gastroesophageal reﬂux disease,
coronary arterial stent insertion,
hyperlipidemia, and hypertension
Acetaminophen/
hydrocodone,
cyclobenzaprine,
chondroitin
w/glucosamine,
and temazepam
Acetaminophen/hydrocodone,
cyclobenzaprine, chondroitin w/
glucosamine, temazepam, lisinopril,
nicotinic acid, omeprazole and
simvastatin
6.6 e 3.0 0.5 13.5 20
Patient 16
78/NA
Back pain and
osteoarthritis
Muscle spasms Paracetamol,
chondroitin, and
glucosamine
Acetylsalicylic acid, chondroitin,
glucosamine, paracetamol, and
omeprazole
4.1 0.7 3.0 0.2 e 20
Patient 17
86/M/29.5
Osteoarthritis
and back pain
Gout, atrial ﬁbrillation, edema
peripheral, hyperlipidemia,
hypertension and Parkinson’s disease
Tramadol Sinemet, dabigatran, and pramipexole 5.3 e 5.1 3.0 10 40
Patient 18
76/F/35.8
Back pain and
osteoarthritis
Depression, blood cholesterol
increased, hypertension, and
hypothyroidism
Lorazepam,
meloxicam,
codeine
phosphate,
and venlafaxine
Meloxicam, lorazepam, venlafaxine,
lovastatin, and levothyroxine
4.7 0.2 2.6 1.6 2.25 20
Patient 19
77/M/28.6
Back pain Anxiety, hypertension, angina pectoris,
and, hyperkalemia
Cyclobenzaprine,
acetaminophen/
hydrocodone,
escitalopram,
and
meloxicam
Cyclobenzaprine, acetaminophen/
hydrocodone, escitalopram,
amlodipine, lisinopril, metoprolol,
glyceryl trinitrate, potassium, and
omeprazole
6.0 5.8 3.1 2.7 18 40
Patient 20
83/F/24.9
Intervertebral
disc degeneration,
back pain, and
osteoarthritis
Neuritis hypertension, facet joint
syndrome, and blood cholesterol
increased
Oxycodone Gabapentin, oxycodone, and
amlodipine
7.6 6.7 4.4 2.8 e 40
Patient 21
77/M/33.6
Osteoarthritis
and back pain
Hypertension Naproxen Amlodipine 5.0 2.00 2.6 0.8 e 40
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K. Broglio et al. / Geriatric Nursing xx (2016) 1e9 5used as required. The safety population included patients who
received at least 1 dose of study drug during the study. Mean and
standard deviations were calculated for continuous variables (age,
weight, body mass index, screening “average pain over the last 14
days,” “average pain over the last 24 h” scores, and pain interfer-
ence scores), while the number and percentage of patients were
described for categorical variables (gender and previous opioid
exposure). Patient characteristics were summarized and analyzed
individually and by group. Safety and effectiveness were assessed
by group. No imputation was performed.
Results
Patient characteristics
The demographics and baseline characteristics of the 24
elderly patients included in this post-hoc analysis are shown in
Table 1. The mean age of the elderly cohort was 78.8 years (range,
75e86 years), and slightly under half of the cohort (45.8%, 11/24)
was female. The overall elderly patient population was over-
weight (mean BMI ¼ 28.4 kg/m2), and presented with moderate
pain and associated functional interference at the initial
screening visit (mean pain score ¼ 6.09 on a 0e10 scale, and
mean pain interference score ¼ 4.97). A majority of the elderly
patients had 6 or more comorbid conditions (92%, 22/24) at
baseline, with a few patients having had as many as 24 active
conditions. Some of the common comorbid conditions included
hypertension (67%, 16/24), hyperlipidemia (42%, 10/24), hypo-
thyroidism (33%, 8/24), gastroesophageal reﬂux disease (29%, 7/
24), depression (21%, 5/24 subjects), hypercholesterolemia (21%,
5/24), insomnia (17%, 4/24 subjects), atrial ﬁbrillation (17%, 4/24),
and constipation (17%, 4/24). Less common comorbid conditions
included coronary artery disease, anxiety, peripheral edema,
peripheral vascular disorder, benign prostatic hyperplasia, and
vulvitis.
Amajority of thepatients had2ormore comorbidpain conditions
(88%; 21/24) at baseline. Back pain (not otherwise speciﬁed [NOS])
(71%, 17/24) and osteoarthritis (NOS) (67%, 16/24) were the most
frequent pain-related conditions observed among the elderly pa-
tients.Otherpainconditions reported includedarthralgia (29%, 7/24),
intervertebral disc degeneration (21%, 5/24), spinal osteoarthritis
(17%, 4/24), musculoskeletal pain (13%, 3/24), spinal column stenosis
(8%, 2/24), facet joint syndrome (8%, 2/24), scoliosis (4%, 1/24), and
spinal compression fracture (4%, 1/24). Patients also reported
depression (21%, 5/24), peripheral neuropathy (13%, 3/24), and
insomnia (17%, 4/24), which may have inﬂuenced pain perception.
A majority of the elderly patients (75%, 18/24) received 5 or
more medications at baseline, with a few patients receiving as
many as 8 to 16 medications. Other than medication used for
treatment of chronic pain, the most common of these medications
included lipid modifying agents (75%, 18/24 patients), antith-
rombotic agents (67%, 16/24 patients), adrenergic beta-receptor
blockers (38%, 9/24), angiotensin-converting-enzyme (ACE) in-
hibitors (38%, 9/24), drugs for acid-related disorders (33%, 8/24),
urologicals (33%, 8/24), psycholeptics (29%, 7/24), and thyroid
therapies (29%, 7/24). All patients received treatment for pain
(opioid and/or non-opioid analgesics) prior to the start of the study;
commonly prescribed medications were opioid plus non-opioid
analgesic combination products (50%, 12/24), NSAIDs (42%, 10/24),
opioids (25%, 6/24), and acetaminophen (17%, 4/24). In addition,
antidepressants and gamma-aminobutyric acid receptor-
modulating drugs may have provided pain relief in patients
suffering from depression, insomnia, and anxiety prior to the
commencement of the study. Patients also obtained pain relief
using muscle relaxants (17%, 4/24) and supplements such as
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the time of screening, 12 patients (50%) were considered opioid-
naive; the other 12 patients (50%) were considered opioid-
experienced. The average screening opioid daily dose was
equivalent to 14.1 mg hydrocodone.
Of the 24 patients 75 years enrolled in the study, 20 (83%)
completed the titration period (Tables 1 and 2) and enrolled into
the maintenance phase of the study, while 4 discontinued due to
titration failure (3 patients due to AEs and 1 due to medical history
not meeting entry criteria). Among patients entering the mainte-
nance phase of the study, 70% (14/20 patients) completed the study
while 6 patients withdrew from the study (Table 2). Of the 12 pa-
tients who were opioid-naïve at baseline, 7 (58%) completed the
study. Of the 6 patients who did not complete the maintenance
phase, 4 discontinued due to AEs, and 2 patients withdrew them-
selves from the study (1 patient could no longer keep the ap-
pointments, the other patient withdrew without explanation).
Among the 20 elderly patients who continued into the main-
tenance phase, the majority was receiving 40 mg HYD dose; 6
patients received 20 mg and 10 received 40 mg (Table 1). Four
patients were treated at doses 60 mg HYD; 1 received 60 mg, 2
received 80 mg, and 1 received 120 mg. Patients who discontinued
due to titration failure received HYD 20 mg (2 patients), 40 mg (1
patient), and 60 mg (1 patient). Among the patients who dis-
continued the study during maintenance, 3 received HYD 20 mg,
while 2 received 40 mg, and 1 received 80 mg at the time of
discontinuation. Of the 14 patients who completed the study, ter-
minal HYD daily doses of 20, 40, 60, 80, and 120 mg were admin-
istered to 3, 5, 4, 1, and 1 patient(s), respectively.
During the study, all elderly patients received concomitant
medications, and 8 (33%) patients received non-study opioid
medications (vs 16 patients at baseline). Six of these 8 patients
continued their pre-study opioid medications on an as-needed
basis during the study; 2 patients (patients 6 and 8) were opioid-
naïve at baseline and received non-study opioid medications dur-
ing the study.HYD effectiveness
Mean “pain over the last 24 h” scores decreased from moderate
(6.1) tomild levels (3.9) by the end of the titration period, and levels
remained mild throughout the maintenance phase until the end of
study (3.6; Fig. 1). A decrease of 2.46 points in the mean “pain over
the last 24 h” scores from baseline levels to the end of the studywasTable 2
Summary of patient disposition and reasons for discontinuation from HYD for pa-
tients 75 years old: safety population.
Dose titration
period
(N ¼ 24)
n (%)
Maintenance
period
(N ¼ 20)
n (%)
Overall
treatment
period
(N ¼ 24) n (%)
Completed period on HYD 20 (83) 14 (70) 14 (58)
Discontinued study 4 (17) 6 (30) 10 (42)
Reason for discontinuation
Adverse event 3 (13) 4 (20) 7 (29.2)
Patient’s choice 0 2 (10) 2 (8)
Lost to follow-up 0 0 0
Lack of therapeutic effect 0 0 0
Conﬁrmed or suspected
diversion
0 0 0
Administrative 0 0 0
Did not qualify for
maintenance period
1 (4) NA 1 (4)
HYD, hydrocodone bitartrate; N, number of patients in the population for the given
period; n, number of patients with each individual response; NA, not available.demonstrated with HYD treatment. During the overall mainte-
nance period, mean pain severity decreased by 2.3 and interference
scores decreased by 2.0 points. A majority of patients were
administered a single, stable HYD dosage throughout the mainte-
nance phase (55%) (Fig. 2). Twenty percent of patients decreased
their HYD dosage during the maintenance phase, while another
20% and 5% increased their HYD dosage by 1 level (eg, HYD 20e
40 mg) and 2 levels (eg, HYD 20 to 40e60 mg), respectively.
The mean HYD dose administered increased from 24.2 mg to
40.8 mg during the titration period, and remained relatively stable
(37.6e49.7 mg range) during the maintenance phase (Fig. 3). The
use of non-study opioid analgesics decreased among study partic-
ipants during the course of the study, declining from 7.9 mg to
1.9 mg in the titration phase and diminishing further during
maintenance.
Treatment satisfaction
Of the 20 patients completing the titration period and entering
the maintenance period of this study, 17 completed the treatment
satisfaction questionnaire. Ninety-four percent (16/17) of patients
indicated high levels of satisfaction (satisﬁed to extremely satisﬁed)
with the study drug. All patients (100%) found it convenient to use
HYD, 94% (16/17) of patients were satisﬁed with the ease and fre-
quency of use of the study drug, and 88% of patients (15/17) were
satisﬁed with the effectiveness of HYD at managing their pain.
Overall, 94% (16/17) of patients were satisﬁed with the study drug,
while all (100%) patients found it easy to plan HYD use.
Safety
Treatment-emergent AEs were reported by 71% of the patients
(Table 3). The most frequently observed AEs were gastrointestinal
disorders, including constipation (54%), nausea (17%), vomiting
(8%), and dry mouth (4%). Overall, 7 of 24 patients (29%) dis-
continued due to an AE during the titration and maintenance pe-
riods (Table 2), with nausea and constipation being the only AEs
leading to discontinuation that were reported in more than 1 pa-
tient. There was no incidence of falls. One patient reported hypo-
gonadism, whereas hyperalgesia and immunosuppressionwere not
assessed due to the lack of standardized testing. There were no
deaths. Serious AEs were reported for 5 (21%) patients: 1 patient
(patient 4) with a history of multiple cardiovascular disorders,
including congestive heart failure and coronary artery disease, re-
ported atypical chest pain; 1 patient (patient 6) with a history of
peripheral vascular disorder and hypertension reported stenosis of
the right internal carotid artery; 1 patient (patient 8) with a history
of pulmonary embolism in the left lung reported bilateral pulmo-
nary embolism, deep vein thrombosis in the left leg, and kidney
stones; 1 patient (patient 22) with a history of pulmonary embo-
lism reported lethargy and pneumonia; and 1 patient (patient 23)
with a history of adenoiditis, mastoiditis, and vulvitis reported
Methicillin-resistant Staphylococcus aureus-infected abscesses of
perineum and buttocks. The serious AE of lethargy reported by 1
patient was the only serious AE to be considered by the investigator
to be possibly study drug related. All other serious AEs were
considered by the investigator to be not related to study drug.
Discussion
In this post-hoc analysis, HYD treatment was clinically effective
in providing sustained reduction of pain scores over a 52-week
period in the elderly patients with chronic pain. These reductions
are considered clinically important (ie, a reduction in pain scores of
2 points and a reduction in BPI-SF pain interference scores of 1
Fig. 1. Mean “average pain over the last 24 h” scores. DT, dose titration period; SE, standard error.
K. Broglio et al. / Geriatric Nursing xx (2016) 1e9 7point).16,17 These patients achieved optimal treatment effects
without requiring high doses of HYD (40mg) and their HYD doses
were stable throughout the 52-week maintenance period. Upon
conversion to HYD treatment, these patients also reduced the use of
other immediate-release or permitted short-acting opioids
throughout the study. This elderly patient subgroup was also
satisﬁed with the ease of use and convenience of HYD treatment.
Overall these results of effectiveness of HYD treatment in the
elderly patients was consistent with the results observed in the
younger patient cohort (<65 years of age)18,19 and the overall study
population from the primary study.14
The AE safety proﬁle shown for HYD is consistent with those
frequently seen in opioid analgesics in general.20,21 HYD treatment
was generally well tolerated among the elderly patients in this
study. The events rates for AEs observed in this study are consistent
with a previous analysis among patients receiving opioid therapy
for chronic nonmalignant pain.22 Although reports indicate that
elderly patients taking opioid medications are at increased risk for
falls and fractures,23,24 no falls were reported in this study. No other
signiﬁcant concerns reported with opioid use were evident in this
study, such as hyperalgesia, endocrine dysfunction, and immuno-
suppression.25e27 In a separate analysis, the adverse event proﬁle in55.0%
20.0%
5.0%
20.0%
No change
Increase of 1 level
Increase of 2 levels
Decrease
Fig. 2. HYD dose changes during the maintenance period of the study.this elderly subgroup was similar to that of younger patients <65
years of age.18,19 Although higher incidence of serious AEs were
reported by the elderly group, compared to the younger cohort, all
serious AEs were more likely a consequence of comorbid disease,
and considered to be unrelated to the study drug with the excep-
tion of the serious AE of lethargy reported in 1 patient, which was
considered to be possibly related to HYD use.
Once-daily HYD differs from the existing opioid formulations.
Unlike the most frequently prescribed opioid hydrocodone-
acetaminophen combination products,28 HYD does not contain a
non-opioid component, therefore its dosage is not limited by po-
tential toxicities associated with the non-opioid component in
combination products, such as liver toxicity with acetaminophen.
Although acetaminophen use is recommended as a ﬁrst-line ther-
apy for the treatment of pain and is generally considered safe, with
a safety proﬁle comparable between older (>65 years) and younger
adults,5 acetaminophen-associated liver toxicity is the leading
cause of acute liver failure in the US.29 In light of this association,
the FDA has put forth a guidance to limit exposure to acetamino-
phen, especially when used chronically at higher doses, or when
used in patients with liver insufﬁciency or alcohol use.30,31 In light
of the current guidance, treatment of the elderly with acetamino-
phen should be closely monitored, since elderly patients taking
medications which increase the activity of enzymes involved in
phase I metabolism may be at increased risk for acetaminophen-
induced hepatotoxicity.29
HYD is dosed every 24 h, affording once-daily dosing, which is
associated with improved adherence rates relative tomultiple daily
doses.32 In addition, a study showed that after administration of
HYD, the pharmacokinetic proﬁle of hydrocodone in healthy elderly
subjects (65e77 years) was similar to that in healthy younger
subjects (20e45 years).11 Thus, conversion to HYD requires no
additional dose adjustment other than those that are routinely
recommended when converting from one opioid to another in an
elderly population.5,7,33 Although the rates of opioid abuse or
misuse among those 60 years of age or older are lower than that of a
younger population,34 the problem of misuse and abuse among
Fig. 3. Average daily HYD and supplemental opioid dose. SE, standard error.
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abuse-deterrent properties that are intended to deter tampering
and misuse by certain avenues of administration.11
This analysis of a subpopulation of a larger study is limited by its
post-hoc nature and small population size. As such, this sub anal-
ysis was not designed to have the speciﬁcity that might have been
used for a study of an exclusively older population. Of note, the
results from this elderly patient subpopulation are similar to those
seen with the entire patient population14 and the younger patient
population19 from the same study.
An additional limitation of this study is the lack of a formal test
for cognition. Pain report is the most reliable pain assessment
source,7 yet many elderly patients can suffer from cognitive im-
pairments that can lead to difﬁculties in accurately reporting painTable 3
Incidence of treatment-emergent adverse events by system organ class and opioid-
related preferred term for patients 75 years old: safety population.
MedDRA system organ class preferred term Total (N ¼ 24) n (%)
Any TEAEa 17 (71)
Endocrine disorders 1 (4)
Hypogonadism 1 (4)
Gastrointestinal disorders 13 (54)
Constipation 13 (54)
Nausea 4 (17)
Vomiting 2 (8)
Dry mouth 1 (4)
General disorders and administration site conditions 5 (21)
Fatigue 4 (17)
Edema peripheral 1 (4)
Nervous system disorders 6 (25)
Dizziness 4 (17)
Headache 1 (4)
Sedation 1 (4)
Skin and subcutaneous tissue disorders 1 (4)
Pruritus 1 (4)
TEAE, treatment-emergent adverse event.
a Any TEAE represents the total number of patients with a TEAE in any of the
treatment periods. Multiple occurrences of the same adverse event in 1 individual
are counted only once. Categories are based on Medical Dictionary for Regulatory
Activities (MedDRA) coding dictionary, version 16.0.levels or the incidence of AEs.37 Although no formal cognitive
studies were conducted on the elderly population in this study,
patients were enrolled in this study only if they were assessed by
the investigator as capable of providing subjective assessments,
and were able to read, understand and respond to questionnaires.
Moreover, this study used an 11-point NRS to assess pain intensity,
a measure that has been validated for use in elderly patient pop-
ulations.10,15 Finally, although patients participating in this study
had access to medication at no cost, it remains to be determined
whether the availability of HYD in the real-world is affected by
accessibility considerations.
Conclusions
In this post-hoc analysis of a long-term study, treatment with
HYD resulted in reduced pain scores that were maintained over a
52-week period in geriatric patients, a growing and complex pop-
ulation to treat. Administration of HYD resulted in clinically
meaningful reductions in mean “pain over the last 24 h” scores and
pain interference scores, and provided signiﬁcant pain relief to
elderly patients for a duration of 52 weeks. A majority of patients
received a stable dose of HYD during the maintenance period of the
study. Additionally, these patients were able to achieve adequate
analgesia without the use of supplemental non-study opioid
medications at the end of the study. Furthermore, patients indi-
cated high levels of satisfaction with HYD. The tolerability of HYD
among geriatric patients was typical for an opioid, although no falls
were observed in this study.
Conﬂicts of interest
This study was sponsored by Purdue Pharma L.P. (Stamford, CT).
Kathleen Broglio is a consultant for Purdue Pharma L.P. Joseph
Pergolizzi is a consultant for Purdue Pharma L.P. andMundipharma.
Maribeth Kowalski and Ellie He are full-time employees of Purdue
Pharma L.P. Warren Wen and Shau Yu Lynch were full-time em-
ployees of Purdue Pharma L.P. at the time this study was conducted.
Editorial support was provided by Sameera Kongara, PhD, of QSci
Communications and funded by Purdue Pharma L.P.
K. Broglio et al. / Geriatric Nursing xx (2016) 1e9 9References
1. Administration on Aging. Department of Health and Human Services. A Proﬁle of
Older Americans, http://www.aoa.gov/Aging_Statistics/Proﬁle/2013/docs/
2013_Proﬁle.pdf; 2013. Accessed 03.03.16.
2. Rottenberg Y, Jacobs JM, Stessman J. Prevalence of pain with advancing age
brief report. J Am Med Dir Assoc. 2015;16:264.e1ee5.
3. Molton IR, Terrill AL. Overview of persistent pain in older adults. Am Psychol.
2014;69:197e207.
4. Gibson SJ, Helme RD. Age-related differences in pain perception and report.
Clin Geriatr Med. 2001;17:433e456. v-vi.
5. Malec M, Shega JW. Pain management in the elderly. Med Clin North Am.
2015;99:337e350.
6. American Geriatrics Society Panel on Pharmacological Management of Persis-
tent Pain in Older Persons. Pharmacological management of persistent pain in
older persons. J Am Geriatr Soc. 2009;57:1331e1346.
7. Rastogi R, Meek BD. Management of chronic pain in elderly, frail patients:
ﬁnding a suitable, personalized method of control. Clin Interv Aging. 2013;8:
37e46.
8. Wilder-Smith OHG. Opioid use in the elderly. Eur J Pain. 2015;9:137e140.
9. Atkinson TJ, Fudin J, Pandula A, Mirza M. Medication pain management in the
elderly: unique and underutilized analgesic treatment options. Clin Ther.
2013;35:1669e1689.
10. Tracy B, Sean Morrison R. Pain management in older adults. Clin Ther. 2013;35:
1659e1668.
11. HYSINGLA  ER (Hydrocodone Bitartrate) Extended Release Tablets for Oral Use,
CII [Package Insert]. Stamford, CT: Purdue Pharma L. P.; 2014.
12. WenW, Sitar S, LynchSY,HeE, Ripa SR. Amulticenter, randomized, double-blind,
placebo-controlled trial to assess the efﬁcacy and safety of single-entity, once-
daily hydrocodone tablets in patients with uncontrolled moderate to severe
chronic low back pain. Expert Opin Pharmacother. 2015;16(11):1593e1606.
13. U.S Department of Health and Human Services. Draft Guidance for Industry.
Analgesic Indications:DevelopingDrugandBiological Products. Available at: http://
www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM384691.pdf; February 2014. Accessed 02.03.16.
14. Wen W, Taber L, Lynch SY, He E, Ripa S. 12-Month safety and effectiveness of
once-daily hydrocodone tablets formulated with abuse-deterrent properties in
patients with moderate to severe chronic pain. J Opioid Manag. 2015;11(4):
339e356.
15. Herr K. Pain assessment strategies in older patients. J Pain. 2011;12:S3eS13.
16. Farrar JT, Young Jr JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of
changes in chronic pain intensity measured on an 11-point numerical pain
rating scale. Pain. 2001;94:149e158.
17. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance
of treatment outcomes in chronic pain clinical trials: IMMPACT recommen-
dations. J Pain. 2008;9:105e121.
18. Wen W, Lynch SY, Ripa S, He E. Evaluation of Once-daily Hydrocodone
(Hysingla  ER) in Patient Subgroups. 2015 The American Academy of Pain Med-
icine Annual Meeting. March 19-22, 2015. Maryland, US: National Harbor; 2015.
19. Bartoli A, Michna E, He E, Wen W. Pain intensity and interference with func-
tioning and well-being in subgroups of chronic pain pateints treated with
once-daily hydrocodone tablets. J Opioid Manag. 2015;11(6):519e533.20. Papaleontiou M, Henderson Jr CR, Turner BJ, et al. Outcomes associated
with opioid use in the treatment of chronic noncancer pain in older adults:
a systematic review and meta-analysis. J Am Geriatr Soc. 2010;58:
1353e1369.
21. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects.
Pain Physician. 2008;11:S105eS120.
22. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-
malignant pain: systematic review of randomised trials of oral opioids.
Arthritis Res Ther. 2005;7:R1046eR1051.
23. Miller M, Sturmer T, Azrael D, Levin R, Solomon DH. Opioid analgesics and the
risk of fractures in older adults with arthritis. J Am Geriatr Soc. 2011;59:
430e438.
24. Rolita L, Spegman A, Tang X, Cronstein BN. Greater number of narcotic anal-
gesic prescriptions for osteoarthritis is associated with falls and fractures in
elderly adults. J Am Geriatr Soc. 2013;61:335e340.
25. Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and
risk of pneumonia in older adults: a population-based case-control study. J Am
Geriatr Soc. 2011;59:1899e1907.
26. Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-
cancer pain: higher prevalence of hypogonadism in men than in women. Exp
Clin Endocrinol Diabetes. 2009;117:38e43.
27. Brennan MJ. The effect of opioid therapy on endocrine function. Am J Med.
2013;126:S12eS18.
28. Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other
commonly used opioids in the United States, 2000-2010. Open Med. 2012;6:
e41ee47.
29. Makris UE, Abrams RC, Gurland B, Reid MC. Management of persistent pain in
the older patient: a clinical review. JAMA. 2014;312:825e836.
30. Blieden M, Paramore LC, Shah D, Ben-Joseph R. A perspective on the epide-
miology of acetaminophen exposure toxicity in the United States. Exp Rev Clin
Pharmacol. 2014;7:341e348.
31. Food and Drug Administration (FDA). Drug Safety Communication: Prescription
acetaminophen products to be limited to 325 mg per dosage unit; boxed warning
will highlight potential for severe liver failure. Silver Spring, MD: U.S. Food and
Drug Administration. Available from: www.fda.gov/drugs/drugsafety/
ucm239821.htm; 2011. Accessed 02.03.16.
32. Graziottin A, Gardner-Nix J, Stumpf M, Berliner MN. Opioids: how to improve
compliance and adherence. Pain Pract. 2011;11:574e581.
33. Chau DL, Walker V, Pai L, Cho LM. Opiates and elderly: use and side effects. Clin
Interv Aging. 2008;3:273e278.
34. West NA, Severtson SG, Green JL, Dart RC. Trends in abuse and misuse of
prescription opioids among older adults. Drug Alcohol Depend. 2015;149:
117e121.
35. Joksovic P, Kirwi P, Trevisan L. Prescription pain medication abuse in elderly
[abstract]. Am J Addict. 2013;22:313.
36. Culberson JW, Ziska M. Prescription drug misuse/abuse in the elderly. Geriat-
rics. 2008;63:22e31.
37. Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic
severe pain in the elderly: consensus statement of an international expert
panel with focus on the six clinically most often used World Health Organi-
zation step III opioids (buprenorphine, fentanyl, hydromorphone, methadone,
morphine, oxycodone). Pain Pract. 2008;8:287e313.
